Karyopharm has a month left to salvage its cancer expansion plans

It's crunch time for Karyopharm as company faces potential default next month

Karyopharm faces September default: $65.4M cash against $15.8M debt due Sept 10; Q2 losses $67M as Xpovio sales stagnate. Negotiating lender waiver/refinancing; strategic alternatives (M&A probable) amid rising counterparty risk for Xpovio-dependent partners.